In March 2023, the U.S. Food and Drug Administration approved the first naloxone nasal spray to be available over-the-counter without a prescription. Naloxone nasal spray will become much more accessible nationwide, and a lot of current state regulations will become obsolete. Current state naloxone regulations for pharmacists are poorly calibrated to the medication's safety profile and may impede access to this critical opioid overdose reversal agent. State policymakers should reflect on the unnecessary regulations that were imposed on pharmacist prescribing of naloxone and consider moving to a "standard of care approach" to better enable pharmacists to engage in future public health initiatives.naloxone, pharmacist prescriptive authority, scope of practice, standard of care In March 2023, the U.S. Food and Drug Administration (FDA) approved the first naloxone nasal spray to be available over-thecounter (OTC) without a prescription. 1 Naloxone rapidly reverses an opioid overdose and restores a patient's breathing. 2 Naloxone is safe, has few side effects, and no absolute contraindications. 2,3 Following the FDA action, naloxone nasal spray will likely soon be sold anywhere that nonprescription drugs are available, including gas stations, convenience stores, and vending machines. 4 OTC status will increase the accessibility of naloxone. This follows years of efforts by states to increase access to the medication through community pharmacies. By 2016, 42 states allowed naloxone to be dispensed to patients through either collaborative practice agreements or statewide protocols, and at least five states allowed pharmacists to prescribe naloxone. 5,6 Today, all states have increased access to naloxone through community pharmacies in some fashion, though such laws are often riddled with restrictions that are poorly calibrated to the safety profile of naloxone and its public health potential.We believe that OTC naloxone presents an important case study to rethink how states regulate pharmacist services. Namely, states should seek to transition from hyper-specific, prescriptive regulations to a flexible "standard of care" regulatory framework so that pharmacists can flexibly meet public health needs in a changing patient care environment.